SharePoint
Aide
IRSN, Institut de radioprotection et de sûreté nucléaire

Search our site :

ok

Contact us :

ok
En Fr

Enhancing Nuclear Safety


Research

Publications

Clinical-grade production of human mesenchymal stromal cells: occurrence of aneuploidy without transformation

“Clinical-grade production of human mesenchymal stromal cells: occurrence of aneuploidy without transformation.” Tarte K., Gaillard J., Lataillade J.J., Fouillard L., Becker M., Mossafa H., Tchirkov A., Rouard H., Henry C., Splingard M., Dulong J., Monnier D., Gourmelon P., Gorin N.C., Sensebé L. ; Société française de greffe de moëlle et thérapie cellulaire. Blood. 25 février 2010 ;115(8):1549-53.

Summary

Clinical-grade human mesenchymal stromal cells (MSCs) have been expanded in vitro for tissue engineering or immunoregulatory purposes without standardized culture conditions or release criteria. Although human MSCs show poor susceptibility for oncogenic transformation, 2 recent studies described their capacity to accumulate chromosomal instability and to give rise to carcinoma in immunocompromised mice after long-term culture. We thus investigated the immunologic and genetic features of MSCs expanded with fetal calf serum and fibroblast growth factor or with platelet lysate in 4 celltherapy facilities during 2 multicenter clinical trials. Cultured MSCs showed a moderate expression of human leukocyte antigen-DR without alteration of their low immunogenicity or their immunomodulatory capacity. Moreover, some transient and donor-dependent recurring aneuploidy was detected in vitro, independently of the culture process. However, MSCs with or without chromosomal alterations showed progressive growth arrest and entered senescence without evidence of transformation either in vitro or in vivo. (Blood. 2010;115:1549-1553)
Send Print

Full text

More information


Close

Send to a friend

The information you provide in this page are single use only and will not be saved.
* Required fields

Recipient's email:*  

Sign with your name:* 

Type your email address:*   

Add a message :

Do you want to receive a copy of this email?

Send

Cancel

Close

WP_IMPRIMER_TITLE

WP_IMPRIMER_MESSAGE

Back

Ok